Floatz logo

ONC 206

Recurrent Malignant Central Nervous System Neoplasm

Sabine Mueller, MD, PhDSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Recurrent Malignant Central Nervous System Neoplasm cohort.

Asset / SponsorPhaseRating
CARMUSTINE
SWOG Cancer Research Network
Phase 3B
o6-benzylguanine
SWOG Cancer Research Network
Phase 3B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC

View all 13 →

Same molecule, other indications

ONC 206 is also rated in:

grade II meningiomaDormant
CC
Indicative ·
43 / 100
View asset →
ependymomaDormant
CC
Indicative ·
43 / 100
View asset →
spinal cord gliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →